Sovaldi

Sovaldi
Drug name	Sovaldi
Tradename	Sovaldi
Legal US	Rx-only
Routes of administration	Oral
Class	Antiviral medication
Metabolism	Minimal hepatic metabolism
Elimination half-life	~12–14 hours
Excretion	Renal
CAS number	1190307-88-0

Sovaldi is a brand-name oral nucleotide analog antiviral developed to treat chronic hepatitis C virus infection. It is indicated as part of combination regimens for multiple hepatitis C genotypes and represented a major advance in direct-acting antiviral therapy, influencing public health policy, pharmaceutical pricing debates, and treatment guidelines. The drug rapidly displaced earlier interferon-based regimens and prompted updates to clinical practice recommendations from hepatology and infectious disease organizations.

Medical uses

Sovaldi is used in adults and selected pediatric populations for chronic hepatitis C virus infection, including monoinfection and coinfection contexts such as HIV–hepatitis C coinfection affecting populations treated by CDC, WHO, EASL, and the AASLD. Clinical trials and real-world studies led by investigators at institutions like Mayo Clinic, Johns Hopkins Hospital, Massachusetts General Hospital, and Mount Sinai Medical Center evaluated efficacy across genotypes 1, 2, 3, 4, 5, and 6, often in combination with agents from companies such as Gilead Sciences, AbbVie, and Roche. Treatment regimens informed by guidelines from NIH panels and advisory committees consider prior treatment history, presence of cirrhosis, and liver-transplant candidates managed by centers including Cleveland Clinic and Queen Elizabeth Hospital Birmingham.

Mechanism of action

Sovaldi contains a nucleotide analog that targets the hepatitis C virus RNA-dependent RNA polymerase NS5B, inhibiting viral replication in hepatocytes studied at laboratories like Karolinska Institutet and Imperial College London. Structural biology work from teams at UCSF and University of Cambridge elucidated binding interactions with conserved polymerase motifs analogous to drug–target studies at Harvard Medical School. Biochemical assays conducted in collaboration with researchers at Pasteur Institute and NIAID characterized chain termination and incorporation dynamics leading to suppression of viral RNA synthesis.

Pharmacology

Pharmacokinetic and pharmacodynamic profiles were assessed in trials coordinated by academic centers such as Stanford University School of Medicine, Yale School of Medicine, and University of Pennsylvania Perelman School of Medicine. The compound exhibits oral bioavailability with renal excretion documented by investigators at UCLH and Karolinska University Hospital. Population pharmacology models used by regulatory reviewers at the FDA and the EMA informed dosing adjustments in renal impairment and special populations considered by transplant units like UCLA Health and Columbia University Irving Medical Center. Drug distribution studies referenced work from Scripps Research Institute and Max Planck Institute collaborators.

Dosage and administration

Standard dosing recommendations were derived from phase II and phase III trials conducted at institutions including Duke University Medical Center, University of Texas Southwestern Medical Center, and Vanderbilt University Medical Center. Typical adult dosing involved a fixed daily oral dose administered alongside other direct-acting antivirals produced or studied by firms and groups such as Bristol-Myers Squibb, Merck & Co., and academic consortia affiliated with World Hepatitis Alliance. Treatment duration and combination choices follow consensus statements from panels convened by European Commission-funded networks and national health services such as NHS England.

Adverse effects

Safety data aggregated by pharmacovigilance divisions at regulatory bodies including the FDA and EMA and monitored by clinicians at centers like Johns Hopkins Hospital documented commonly reported adverse effects such as fatigue and headache in trial cohorts enrolled at Cleveland Clinic and Massachusetts General Hospital. Serious adverse events were evaluated by independent data monitoring committees with expertise from Oxford University Hospitals and University of Melbourne, leading to labeling that highlights monitoring in patients with advanced liver disease managed at transplant centers like Hôpital Beaujon and Hopital Saint-Louis.

Drug interactions

Interaction potential was characterized in studies by pharmacology groups at University of Toronto, Seoul National University Hospital, and National University Hospital Singapore. Co-administration considerations include agents metabolized or transported involving pathways studied at NIH Clinical Center and pharmaceutical partners like Pfizer and Novartis. Clinicians coordinate care with specialists in infectious disease and hepatology at institutions such as Mount Sinai Hospital (Toronto) and Royal Free Hospital to manage interactions with antiretroviral therapy for HIV/AIDS treated under guidelines from UNAIDS and national agencies.

History and regulatory approval

Development and commercialization were led by Gilead Sciences, with pivotal trials conducted in collaboration with academic sites including Massachusetts General Hospital, UCSD, and Hospital Clínic de Barcelona. Regulatory submissions to the FDA and EMA followed expedited review pathways based on high sustained virologic response rates demonstrated in phase III trials overseen by data safety boards featuring experts from Harvard Medical School and University of Oxford. Approval and pricing decisions prompted debates involving policy makers from United States Congress, health technology assessment bodies such as NICE, and global public health organizations including the WHO and Médecins Sans Frontières, influencing access programs and licensing agreements in countries represented by ministries of health like those of India and Brazil.

Category:Antiviral drugs